Drugs / GSK3277511A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03894969 | Apr 2019 → Aug 2020 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03443427 | Mar 2018 → Dec 2019 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03281876 | Nov 2017 → Mar 2020 | respiratory system disorder | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3277511A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03894969 ↗ |
| Known as | NTHi Mcat investigational vaccine | “NTHi Mcat investigational vaccine (GSK3277511A)” NCT03443427 ↗ |
| Modality | Vaccine | “investigational vaccine GSK3277511A” NCT03281876 ↗ |
| Route | Intramuscular | “Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.” NCT03281876 ↗ |